Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxicity in AD

🧫 Experiment Protocol ClinicalAlzheimer's DiseaseCAARhumanproposed

# Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated Neurotoxicity in AD ## Background and Rationale Alzheimer's disease (AD) is characterized by progressive neurodegeneration, with emerging evidence suggesting that autoantibodies targeting neuronal antigens contribute to disease pathology beyond amyloid-beta accumulation. Pathogenic autoantibodies against BACE1, AQP4, and various neuronal surface proteins have been detected in AD patients and correlate with cognitive decline and synaptic dysfunction. Traditional immunosuppressive approaches lack specificity and may compromise beneficial immune responses, including protective anti-Aβ antibodies. This phase I/IIa clinical trial evaluates Chimeric Autoantibody Receptor (CAAR) T cell therapy, an innovative approach that selectively targets B cells producing specific pathogenic autoantibodies while preserving the broader B cell repertoire. CAAR-T cells are engineered to express chimeric receptors containing the extracellular domains of target antigens (BACE1, AQP4, neuronal proteins) fused to T cell activation domains. When these receptors bind to surface-bound autoantibodies on pathogenic B cells, they trigger selective T cell-mediated elimination of only those B cells producing the targeted autoantibodies. The study employs a dose-escalation design with comprehensive safety monitoring, enrolling mild-to-moderate AD patients with confirmed presence of target autoantibodies. Primary endpoints include safety, tolerability, and reduction in circulating pathogenic autoantibody levels. Secondary endpoints encompass cognitive assessments, neuroimaging biomarkers, cerebrospinal fluid inflammatory markers, and preservation of protective antibody responses. This precision immunotherapy approach represents a paradigm shift toward antigen-specific immune modulation in neurodegeneration, potentially offering therapeutic benefits while maintaining immune system integrity essential for neuroprotection and pathogen defense. This experiment directly tests predictions arising from the following hypotheses: - **SASP-Mediated Complement Cascade Amplification** - **Complement C1q Mimetic Decoy Therapy** - **Complement C1q Subtype Switching** - **Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation** - **Ocular Immune Privilege Extension** ## Experimental Protocol Phase I: Screening and enrollment of 24 mild-to-moderate AD patients (MMSE 18-26) with confirmed serum levels of anti-BACE1, anti-AQP4, or anti-neuronal autoantibodies ≥2-fold above healthy controls. Patients undergo comprehensive baseline assessments including neuropsychological testing, MRI, CSF collection, and immune profiling. Phase II: CAAR-T cell manufacturing involves leukapheresis followed by T cell isolation, transduction with lentiviral vectors encoding target-specific CAARs, and ex vivo expansion for 10-14 days with quality control testing. Phase III: Dose escalation using 3+3 design with three cohorts receiving 1×10^6, 3×10^6, or 1×10^7 CAAR-T cells/kg via intravenous infusion following lymphodepleting chemotherapy (fludarabine 25mg/m² and cyclophosphamide 250mg/m² for 3 days). Phase IV: Intensive safety monitoring for 28 days including daily vital signs, cytokine release syndrome assessment, and neurological evaluations. Phase V: Long-term follow-up for 12 months with monthly autoantibody measurements, quarterly cognitive assessments (ADAS-Cog, CDR-SB), neuroimaging at 3, 6, and 12 months, and CSF analysis at 6 months. Concomitant medications including acetylcholinesterase inhibitors remain stable throughout the study period. ## Expected Outcomes - Significant reduction in target autoantibody levels by 70-90% from baseline within 4 weeks post-infusion, maintained for at least 6 months - Preservation of protective anti-Aβ antibody levels with <20% reduction from baseline throughout the 12-month follow-up period - Stabilization or improvement in cognitive function with ADAS-Cog scores showing <2-point decline or improvement compared to historical controls showing 4-6 point annual decline - Reduction in CSF inflammatory markers (IL-6, TNF-α, complement C3d) by 40-60% at 6 months compared to baseline - Decreased rate of brain atrophy on MRI with <1% annual hippocampal volume loss compared to 2-4% in untreated AD patients - Manageable safety profile with grade 3-4 adverse events in <30% of patients and no treatment-related deaths ## Success Criteria - ≥50% reduction in target autoantibody levels sustained for ≥3 months in ≥60% of treated patients - Preservation of anti-Aβ antibodies with mean reduction <25% from baseline across all dose cohorts - Cognitive stabilization defined as ADAS-Cog change ≤2 points from baseline at 12 months in ≥50% of patients - Absence of dose-limiting toxicities including severe cytokine release syndrome, autoimmune encephalitis, or opportunistic infections - CSF biomarker improvement with ≥30% reduction in neuroinflammatory markers in ≥40% of evaluable patients - Demonstration of CAAR-T cell persistence and activity with detectable cells at 3 months and continued autoantibody suppression

Source: wiki

🧫 Experiment Extras

🔴 Alzheimer's Disease 🧠 Neurodegeneration

📊 Evidence Profile

0 supporting 0 contradicting 0 neutral

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found